

| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Total Revenue | 1,255.72 | 1,093.79 | 935.58 | 803.41 | 412.03 |
| Total Expenses | 1,084.70 | 964.26 | 843.78 | 717.69 | 365.69 |
| Profit Before Tax | 171.02 | 129.53 | 91.80 | 85.72 | 46.34 |
| Profit After Tax | 128.26 | 94.34 | 67.95 | 63.95 | 34.50 |
| Operating Profit After Depreciation | 173.42 | 150.99 | 111.77 | 91.40 | 50.27 |
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Fixed Assets | 829.87 | 357.88 | 182.88 | 183.03 | 79.14 |
| Total Non Current Assets | 884.71 | 741.13 | 261.95 | 196.42 | 99.15 |
| Total Current Assets | 695.69 | 579.75 | 442.47 | 379.05 | 270.46 |
| Total Assets | 1,580.41 | 1,320.88 | 704.41 | 575.48 | 369.62 |
| Total Shareholder's Fund | 959.42 | 830.89 | 276.51 | 208.61 | 144.82 |
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Net Cash From Operating Activities | 63.84 | 146.34 | 67.12 | 58.90 | 41.57 |
| Net Cash Used In Investing Activities | -151.59 | -498.97 | -90.84 | -188.12 | -19.67 |
| Net Cash Used In Financing Activities | 91.53 | 360.83 | 27.09 | 124.57 | -19.34 |
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Total Revenue | 974.84 | 875.65 | 867.41 | 788.31 | 412.03 |
| Total Expenses | 854.95 | 781.95 | 789.10 | 699.68 | 365.69 |
| Profit Before Tax | 119.89 | 93.70 | 78.31 | 88.63 | 46.34 |
| Profit After Tax | 89.47 | 68.16 | 57.55 | 66.18 | 34.50 |
| Operating Profit After Depreciation | 122.06 | 107.29 | 96.61 | 93.96 | 50.27 |
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Fixed Assets | 637.47 | 163.56 | 161.37 | 161.21 | 79.14 |
| Total Non Current Assets | 836.04 | 717.63 | 299.95 | 231.63 | 99.15 |
| Total Current Assets | 529.11 | 437.44 | 378.38 | 313.28 | 270.46 |
| Total Assets | 1,365.14 | 1,155.07 | 678.34 | 544.91 | 369.62 |
| Total Shareholder's Fund | 812.97 | 723.72 | 268.32 | 210.83 | 144.82 |
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Net Cash From Operating Activities | 19.80 | 111.67 | 39.28 | 58.34 | 41.57 |
| Net Cash Used In Investing Activities | -99.75 | -471.55 | -87.53 | -188.33 | -19.67 |
| Net Cash Used In Financing Activities | 83.86 | 368.13 | 51.29 | 125.30 | -19.33 |
| Particulars (in ₹ Cr.) | 2025-09 | 2025-06 | 2025-03 | 2024-12 | 2024-09 |
|---|---|---|---|---|---|
| Total Revenue | 380.38 | 351.54 | 314.74 | 316.46 | 318.20 |
| Total Expenses | 328.52 | 299.44 | 267.06 | 269.90 | 268.47 |
| Profit Before Tax | 39.23 | 42.67 | 39.31 | 45.59 | 46.81 |
| Profit After Tax | 29.67 | 31.02 | 29.57 | 34.20 | 35 |
| Operating Profit after Depreciation | 56.05 | 56.58 | 51.06 | 50.89 | 51.95 |
| Particulars (in ₹ Cr.) | 2025-09 | 2025-06 | 2025-03 | 2024-12 | 2024-09 |
|---|---|---|---|---|---|
| Total Revenue | 289.83 | 286.98 | 242.52 | 248.53 | 240.18 |
| Total Expenses | 260.51 | 252.15 | 214.34 | 216.03 | 207 |
| Profit Before Tax | 19.26 | 27.30 | 22.86 | 32.78 | 34.31 |
| Profit After Tax | 14.33 | 20.30 | 17.13 | 24.40 | 25.61 |
| Operating Profit after Depreciation | 33.95 | 39.15 | 32.54 | 35.99 | 37.46 |
| Company | Price | Market Cap (in Cr) |
|---|---|---|
| Sun Pharmaceutical Industries Ltd | ₹1,763.70 | ₹4,23,170.71 |
| Divis Laboratories Ltd | ₹6,523.25 | ₹1,73,171.79 |
| Torrent Pharmaceuticals Ltd | ₹3,816.75 | ₹1,29,170.36 |
| Cipla Ltd | ₹1,536.25 | ₹1,24,093.85 |
| Dr Reddys Laboratories Ltd | ₹1,244.50 | ₹1,03,868.61 |
| Fund Name | AUM |
|---|---|
| Kotak Healthcare Fund | 1.62% |
| Canara Robeco Manufacturing Fund | 1.35% |
| Kotak Consumption Fund | 1.07% |
| Canara Robeco Value Fund | 1.03% |
| Canara Robeco Small Cap Fund | 1.02% |
On 7 November 2025
31 Oct 2025, 10:38 am
Innova Captab advanced 1.24% to Rs 910.85 after the company said that its Cephalosporin plant in Baddi, Himachal Pradesh has successfully cleared the United Kingdom Medicines and Healthcare products Regulatory Agency (UK-MHRA) inspection.
21 Aug 2025, 09:49 am
On 7 August 2025
31 Jul 2025, 02:18 pm
On 31 July 2025
03 Jul 2025, 02:59 pm
On 19 May 2025
13 May 2025, 03:59 pm

Get started with us today and
start building your wealth journey
*By clicking, I agree to the T&C and Whatsapp updates.

Get started with us today and
start building your wealth journey
*By clicking, I agree to the T&C and Whatsapp updates.

Congratulations,
Your Digital savings bank account opening journey is complete.